|Test||CANCER ANTIGEN 125|
|Methodology||Electrochemiluminescence Immunoassay (ECLIA)|
|Description||Useful as an aid in the management of cancer patients, particularly in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy.
No sample should be collected on patients receiving therapy with high biotin doses(i.e. biotin therapy for Multiple Sclerosis or oncology patients; skin, hair and nail supplements, or multivitamins containing > 5 mg/day) until at least 12 hours after the last biotin administration. If unsure, or if the clinical picture does not fit the results please contact the laboratory . We have methods to check for biotin interference as well as for any other interferences and for the accuracy of the results.
NOTE: This test, when ordered on Medicare patients, is subject to the National Coverage Determination (NCD) policy "Tumor Antigen by Immunoassay - CA125". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The CMS web site or the NorDx Limited Coverage Documentation Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen.
|Specimen||Draw blood in either a plain, red-top or serum gel tube. Spin down and send 1.0 mL (minimum volume: 0.5 mL) of serum refrigerated.|
|Reference Values||< 38 U/mL|
|Analytic Time||1 Day|
|Day(s) Test Set Up||Monday through Friday|